Zobrazeno 1 - 10
of 44
pro vyhledávání: '"Jeffrey Rubens"'
Autor:
Elizabeth Alva, Jeffrey Rubens, Susan Chi, Tom Rosenberg, Alyssa Reddy, Eric H. Raabe, Ashley Margol
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 37, Iss , Pp 100880- (2023)
Atypical teratoid rhabdoid tumors (AT/RT) are malignant central nervous system (CNS) tumors that occur mostly in young children and have historically carried a very poor prognosis. While recent clinical trial results show that this tumor is curable,
Externí odkaz:
https://doaj.org/article/5c241990d0c5472da5a1d04fc2396d73
Abstract 1141: The CoREST complex as a novel target to disrupt AT/RT’s abnormal epigenetic landscape
Autor:
Anupa Geethadevi, Marianne Collard, Nikhil Vaidya, Tyler Findlay, Kristen Malebranche, Charles Eberhart, Eric Raabe, Philip Cole, Rhoda Alani, Jeffrey Rubens
Publikováno v:
Cancer Research. 83:1141-1141
Atypical teratoid/rhabdoid tumors (AT/RT) are deadly infantile brain tumors. Their aggressive phenotype results from a single recurring biallelic loss-of-function mutation in genes encoding components of the SWI/SNF chromatin-remodeling complex - SMA
Publikováno v:
Cancer Research. 83:4990-4990
Diffuse midline glioma (DMG) is an aggressive pediatric glioma with no curative treatment options. Mutation in MAPK pathway is common in many DMG tumors, however, has not been largely explored before. E6201 is a dual inhibitor of ACVR1 and MEK 1/2. I
Publikováno v:
Cancer Research. 83:6720-6720
H3K27-altered diffuse midline glioma (DMG) and atypical teratoid/rhabdoid tumor (AT/RT) are aggressive pediatric brain tumors with dismal outcomes. DMG and AT/RT have increased baseline activation of the integrated stress response (ISR), an evolution
Autor:
Fausto J. Rodriguez, Jeff S. Mumm, Eric H. Raabe, Liqun Jiang, Jeffrey Rubens, Ming Yuan, Liam Chen, Jennifer Bynum, Eric M. Jackson, Linda M.S. Resar, Charles G. Eberhart, David T. White, Mari L. Groves, Alan R. Cohen, Eli E. Bar
Publikováno v:
Neuro Oncol
Background The conditional reprogramming cell culture method was developed to facilitate growth of senescence-prone normal and neoplastic epithelial cells, and involves co-culture with irradiated fibroblasts and the addition of a small molecule Rho k
Autor:
Eric H. Raabe, Harpreet Kaur, Shubin Shahab, Charles G. Eberhart, Heather Sweeney, Jeffrey Rubens
Publikováno v:
J Neuropathol Exp Neurol
Atypical teratoid/rhabdoid (AT/RT) tumors are the most common malignant brain tumor of infancy and have a poor prognosis. We have previously identified very high expression of LIN28A and/or LIN28B in AT/RT tumors and showed that AT/RT have correspond
Autor:
Jeffrey Rubens, David J. Clark, Lijun Chen, Antje Arnold, Micah J. Maxwell, Hui Zhang, Eric H. Raabe, Tung-Shing M. Lih, Michael Schnaubelt, Heather Sweeney, Charles G. Eberhart
Publikováno v:
Molecular & Cellular Proteomics : MCP
The mitogen-activated protein kinase pathway is one of the most frequently altered pathways in cancer. It is involved in the control of cell proliferation, invasion, and metabolism, and can cause resistance to therapy. A number of aggressive malignan
Autor:
Allison Hanaford, Charles G. Eberhart, Antoinette Price, Harpreet Kaur, Brad Poore, Sariah Allen, Brent A. Orr, Barbara S. Slusher, Jesse Alt, Eric H. Raabe, Jeffrey Rubens, Sabrina Wang
Publikováno v:
Clinical Cancer Research. 25:5925-5936
Purpose: Atypical teratoid/rhabdoid tumors (AT/RT) are aggressive infantile brain tumors with poor survival. Recent advancements have highlighted significant molecular heterogeneity in AT/RT with an aggressive subgroup featuring overexpression of the
Publikováno v:
Cancer Research. 82:5226-5226
Atypical teratoid/rhabdoid tumors (AT/RT) are aggressive pediatric brain tumors and the most common malignant brain tumors of infancy. The four-year event-free survival rate is only 37%. For patients with relapsed AT/RT, there are limited treatment o
Publikováno v:
Cancer Research. 82:5225-5225
Atypical teratoid/rhabdoid tumors (AT/RT) are the most common malignant brain tumors of infancy with a four-year event-free survival of 37%. Previously, we have identified high activation of both mTORC1 and mTORC2 through immunohistochemistry of 18 p